Genentech, Inc.

F. Hoffmann-la Roche Ag

Genetech, Inc.

Timothy Heffron

Robert Andrew Heald

Alan G Olivero

Bryan K Chan

Steven T Staben

Chudi Obioma Ndubaku

Adrian Folkes

Stephen Colin Price

Eileen Mary Seward

Steven Huy Do

Aleksandr Kolesnikov

BinQing Wei

Nicole Blaquiere

Danette Dudley

Michael Lainchbury

Lewis J Gazzard

Emanuela Gancia

Lan Wang

Andrew Madin

Sushant Malhotra

Jun Liang

Rohan V Mendonca

Yonghan Hu

John Tellis

Mark Jones

Michael Siu

Graham Elgin Jones

Craig Stivala

Joy Drobnick

Matthew W Cartwright

Weiru Wang

Kin Chiu Fong

Binqing Wei

Jennafer Dotson

David Favor

Andrew Good

Richard A Goldsmith

Naomi S Rajapaksa

Richard Leonard Elliott

Aihe Zhou

Daniel P Sutherlin

Emily J Hanan

Aijun Lu

Marian C Bryan

Baihua Hu

Blake Daniels

Malcolm Huestis

Neville James McLean

Edna F Choo

Sussie Lerche Krintel

Laurent Salphati

Chudi Ndubaku

Joseph P Lyssikatos

Bing-Yan Zhu

Zachary Kevin Sweeney

Anthony A Estrada

Brian Salvatore Safina

Charles Baker-Glenn

Irina Chuckowree

Shumei Wang

Nan Chi Wan

Terry Aaron Panchal

Toby Jonathan Blench

Terry Kellar

Hans Purkey

Bohdan Waszkowycz

Elsa Amandine Dechaux

Jamie Knight

Francois Diederich

BinQuing Wei

Adrian J Folkes

Neville James Mclean

Joseph Lyssikatos

Steven Do

Stephen Price

Steven Staben

Robert Heald

Naomi Rajapaksa

John C Tellis

3-Carbonylaminoisoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the 3-carbonylaminoisoquinoline compounds.

Isoquinoline compounds for the treatment of cancer

Isoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.

Isoquinoline compounds and uses thereof

Naphthyridine compounds and uses thereof

Spirocyclic 2,3-dihydro-7-azaindole compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the spirocyclic 2,3-dihydro-7-azaindole compounds.

Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof

Azaindole compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the azaindole compounds.

Azaindoles as inhibitors of HPK1

3-Carbonylamino-8-aminoisoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the 3-carbonylamino-8-aminoisoquinoline compounds.

8-aminoisoquinoline compounds and uses thereof

Isoquinoline compounds and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.

Isoquinolines as inhibitors of HPK1

Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.

Naphthyridines as inhibitors of HPK1

This invention relates to novel compounds which are inhibitors of T790M containing EGFR mutants, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of cancer.

Azaindazole compounds as inhibitors of T790M containing EGFR mutants

Aminopyrimidine compounds as inhibitors of T790M containing EGFR mutants

Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Zis CRor N; Zis CRor N; Zis CRor N; Zis CRor N; and B is a pyrazolyl, imidazolyl, or triazolyl ring fused to the benzoxepin ring, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Benzoxazepin PI3K inhibitor compounds and methods of use

Tricyclic PI3k inhibitor compounds of Formula I with anti-cancer activity, anti-inflammatory activity, or immunoregulatory properties, and more specifically with PI3 kinase modulating or inhibitory activity are described. Methods are described for using the tricyclic PI3K inhibitor compounds of Formula I for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, organisms, or associated pathological conditions.  Formula I compounds include stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof. The dashed lines indicate an optional double bond, and at least one dashed line is a double bond. The substituents are as described.

Tricyclic PI3K inhibitor compounds and methods of use

Growing community of inventors

Burlingame, CA, United States of America

Timothy Heffron